Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
10 mai 2022 06h30 HE
|
Verve Therapeutics
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and...
Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
09 mai 2022 06h30 HE
|
Verve Therapeutics
VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101...
Verve Therapeutics to Participate in Upcoming May Investor Conferences
04 mai 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
26 avr. 2022 06h30 HE
|
Verve Therapeutics
Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing...
Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
04 avr. 2022 06h30 HE
|
Verve Therapeutics
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st...
Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
24 mars 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
14 mars 2022 06h30 HE
|
Verve Therapeutics
Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight...
Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
23 févr. 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
10 janv. 2022 06h30 HE
|
Verve Therapeutics
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data...
Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03 janv. 2022 06h30 HE
|
Verve Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...